Form 4: RxSight Director Robert Palmisano Granted 10,752 Restricted Stock Units, Boosting Total Holdings
Insider Transaction Report
RxSight, Inc. Director Robert J. Palmisano was granted 10,752 restricted stock units (RSUs) on June 3, 2025, increasing his total beneficial ownership to 41,039 shares of common stock.
Summary
- Robert J. Palmisano, a Director of RxSight, Inc. (RXST), acquired 10,752 restricted stock units (RSUs) on June 3, 2025.
- Each RSU represents a contingent right to receive one share of RxSight, Inc. Common Stock.
- Following this transaction, Mr. Palmisano's direct beneficial ownership of RxSight common stock stands at 41,039 shares.
- The RSUs are subject to a vesting schedule, with 100% vesting on the earlier of the one-year anniversary of the grant date (June 3, 2025) or the date immediately prior to the next annual meeting of stockholders, contingent on Mr. Palmisano's continued service as an Outside Director.
Sentiment
Score: 7
Explanation: The grant of RSUs to a director is a positive indicator of alignment and confidence, though it's a standard compensation practice rather than a direct investment.
Positives
- The grant of restricted stock units to a director aligns management's interests with those of shareholders, as the value of the RSUs is tied to the company's stock performance.
- The increase in a director's beneficial ownership can signal confidence in the company's future prospects.
Future Outlook
The acquired restricted stock units are scheduled to vest 100% on the earlier of the one-year anniversary of the grant date (June 3, 2025) or the date immediately prior to the next annual meeting of stockholders, provided the reporting person continues as an Outside Director.
Industry Context
This Form 4 filing details a routine insider transaction related to director compensation, which is a common practice across publicly traded companies to align executive and director interests with shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Authorization | Robert Palmisano granted a Power of Attorney to several individuals, including Ron Kurtz, Shelley Thunen, Martin J. Waters, Robert L. Wernli, Jr., Michael Brito-Stamm, Mahnaz Dodge, and Bridget Balisy, to prepare and file SEC reports (Forms 3, 4, 5, Schedules 13D, 13G, and Forms 144) on his behalf, ensuring compliance with Section 13 and 16 of the Exchange Act and Rule 144. | 2024-06-13 | Enhances efficiency and ensures timely compliance with SEC reporting requirements for insider transactions and beneficial ownership disclosures. |
Related Party Transactions
- The grant of restricted stock units to Robert J. Palmisano, a director, constitutes a transaction between the company and a related party (an insider) as part of his compensation.
Stakeholder Impact
- Shareholders: The RSU grant aligns the director's financial interests with shareholder value, as the RSUs' value is tied to the company's stock performance, potentially fostering long-term growth.
Next Steps
- Vesting of the 10,752 restricted stock units on the earlier of June 3, 2026, or the day before the next annual meeting of stockholders, subject to continued service.
Key Dates
| Date | Description |
|---|---|
| 2024-06-13 | Date of execution for the Power of Attorney granted by Robert Palmisano. |
| 2025-06-03 | Date of grant for 10,752 restricted stock units (RSUs) to Robert J. Palmisano. |
| 2025-06-04 | Date the Form 4 was signed by Robert L. Wernli, Jr., as Attorney-in-Fact for Robert J. Palmisano. |
Keywords
RxSight, RXST, Form 4, insider transaction, restricted stock units, RSU, director compensation, equity incentive plan, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.